The clinical effects of different concentrations of ropivacaine combined with dexmedetomidine for epidural labor analgesia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200067052

Enrollment

Unknown

Registered

2022-12-26

Start date

2021-10-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

labor analgesia

Interventions

Group A:0.1% ropivacaine combined with 0.5 ug/ml dexmedetomidine for epidural labor analgesia

Group B:0.075% ropivacaine combined with 0.5 ug/ml dexmedetomidine for epidural labor analgesia

Group C:0.06% ropivacaine combined with 0.5 ug/ml dexmedetomidine for epidural labor analgesia

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: ASA grade I-II, age 20-35 years, height 1.50-1.72m, BMI 20.0-30.9kg/m2, cervical opening 2-3cm, and without other systemic diseases, obstetric complications and contraindications to anesthesia

Exclusion criteria

Exclusion criteria: Failure of analgesia pump, local anesthetic poisoning, total spinal anesthesia, epidural catheter prolapse during labor analgesia

Design outcomes

Primary

Measure	Time frame
Analgesic effect;adverse reaction;	—

Secondary

Measure	Time frame
labor time;neonatal Apgar score;Blood pressure;heart rate;saturation of pulse oximetry;Ramsay sedation scores;neonatal umbilical artery pH;	—

Countries

China

Contacts

Public ContactChen Xiang

Wenzhou People's Hospital

387625332@qq.com+86 13732018099

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026